A Pfizer whistleblower revealed that employees were given a “separate and distinct” COVID-19 vaccine than the general public.
Employees at Pfizer’s Pearl River research site were offered the “distinct” vaccine.
The Pearl River site is the “primary research and development center housing activities relating to Pfizer’s collaboration with BioNTech, which is focused on developing a potential mRNA-based coronavirus vaccine aimed at preventing COVID-19 infection,” according to its website.
“I am pleased to inform you that we will begin offering COVID-19 vaccinations to eligible on-site essential colleagues and contractors over the next several weeks,” reads the leaked email, obtained exclusively by Infowars. “Eligible on-site essential contractors will be notified, either by e-mail or by their Pfizer sponsor, and will receive instructions for registering for an on-site appointment as well.”
“I know we employees at Pfizer were receiving different vaccines and/or placebos and this was the word around my site when I worked there,” the whistleblower told the outlet.
The email notes that these vaccines are “separate and distinct” from those provided to “governments around the world.”
“The vaccine doses to be used for this program are separate and distinct from those committed by Pfizer to governments around the world and will not impact supply to national governments in any way,” the email says.
American Faith reported that sales of Pfizer’s COVID-19 vaccine declined by 70% in 2023.
The vaccine company pointed to “lower contracted deliveries and demand in international markets and lower U.S. government contracted deliveries, due to transition to new variant vaccines in most markets and the transition to traditional U.S. commercial market sales which began in September 2023,” as reasons for the decline, according to a filing.
Last year, Pfizer’s revenue on the vaccine was $11.2 billion. In 2022, the company’s vaccine revenue was $37 billion.
Pfizer’s total revenues decreased 42%, down to $58.5 billion from $100.33 billion.